776 related articles for article (PubMed ID: 17991309)
1. Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction.
Axilrod AC
Curr Med Res Opin; 2007 Dec; 23(12):3189-98. PubMed ID: 17991309
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase 5 inhibitors for erectile dysfunction.
Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
[TBL] [Abstract][Full Text] [Related]
3. PDE5 inhibitors: are there differences?
Carson CC
Can J Urol; 2006 Feb; 13 Suppl 1():34-9. PubMed ID: 16526979
[TBL] [Abstract][Full Text] [Related]
4. Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors.
Hellstrom WJ
Int J Clin Pract; 2007 Sep; 61(9):1547-54. PubMed ID: 17655683
[TBL] [Abstract][Full Text] [Related]
5. The evolving role of testosterone in the treatment of erectile dysfunction.
Shabsigh R; Rajfer J; Aversa A; Traish AM; Yassin A; Kalinchenko SY; Buvat J
Int J Clin Pract; 2006 Sep; 60(9):1087-92. PubMed ID: 16939550
[TBL] [Abstract][Full Text] [Related]
6. PDE5 inhibitors beyond erectile dysfunction.
Sandner P; Hütter J; Tinel H; Ziegelbauer K; Bischoff E
Int J Impot Res; 2007; 19(6):533-43. PubMed ID: 17625575
[TBL] [Abstract][Full Text] [Related]
7. Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK.
Kell PD; Hvidsten K; Morant SV; Harnett JP; Bridge S
BJU Int; 2007 Apr; 99(4):860-3. PubMed ID: 17378846
[TBL] [Abstract][Full Text] [Related]
8. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences.
Greco EA; Spera G; Aversa A
Eur Urol; 2006 Nov; 50(5):940-7. PubMed ID: 16979814
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase type 5 inhibitors for erectile dysfunction.
Carson CC; Lue TF
BJU Int; 2005 Aug; 96(3):257-80. PubMed ID: 16042713
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors.
Sussman DO
J Am Osteopath Assoc; 2004 Mar; 104(3 Suppl 4):S11-5. PubMed ID: 15083994
[TBL] [Abstract][Full Text] [Related]
11. Acceptance of and discontinuation rate from erectile dysfunction oral treatment in patients following bilateral nerve-sparing radical prostatectomy.
Salonia A; Gallina A; Zanni G; Briganti A; Dehò F; Saccà A; Suardi N; Barbieri L; Guazzoni G; Rigatti P; Montorsi F
Eur Urol; 2008 Mar; 53(3):564-70. PubMed ID: 17761385
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and management of erectile dysfunction in the primary care setting.
Rosenberg MT
Int J Clin Pract; 2007 Jul; 61(7):1198-208. PubMed ID: 17577299
[TBL] [Abstract][Full Text] [Related]
13. [Novel indications for phosphodiesterase type 5 inhibitors].
Rosenkranz S; Caglayan E; Erdmann E
Med Klin (Munich); 2007 Aug; 102(8):617-30. PubMed ID: 17694282
[TBL] [Abstract][Full Text] [Related]
14. Erectile dysfunction therapy in special populations and applications: coronary artery disease.
DeBusk RF
Am J Cardiol; 2005 Dec; 96(12B):62M-66M. PubMed ID: 16387570
[TBL] [Abstract][Full Text] [Related]
15. Global experiences with vardenafil in men with erectile dysfunction and underlying conditions.
Eardley I; Lee JC; Guay AT
Int J Clin Pract; 2008 Oct; 62(10):1594-603. PubMed ID: 18822030
[TBL] [Abstract][Full Text] [Related]
16. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.
Kloner RA
Am J Cardiol; 2005 Dec; 96(12B):42M-46M. PubMed ID: 16387566
[TBL] [Abstract][Full Text] [Related]
17. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A;
Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
[TBL] [Abstract][Full Text] [Related]
18. Erectile dysfunction, discrepancy between high prevalence and low utilization of treatment options: results from the 'Cottbus Survey' with 10 000 men.
May M; Gralla O; Knoll N; Fenske S; Spivak I; Rönnebeck C; Hoffmann M; Lenk S; Hoschke B
BJU Int; 2007 Nov; 100(5):1110-5. PubMed ID: 17922788
[TBL] [Abstract][Full Text] [Related]
19. The therapeutic dilemma: how to use short-acting PDE5 inhibitor drugs.
Fabbri A; Aversa A
Int J Androl; 2005 Dec; 28 Suppl 2():69-73. PubMed ID: 16236069
[TBL] [Abstract][Full Text] [Related]
20. Rationale for phosphodiesterase 5 inhibitor use post-radical prostatectomy: experimental and clinical review.
Rambhatla A; Kovanecz I; Ferrini M; Gonzalez-Cadavid NF; Rajfer J
Int J Impot Res; 2008; 20(1):30-4. PubMed ID: 17673932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
